

# Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) - Drugs In Development, 2021

<https://marketpublishers.com/r/I69C0ED446F9EN.html>

Date: July 2021

Pages: 291

Price: US\$ 2,000.00 (Single User License)

ID: I69C0ED446F9EN

## Abstracts

Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) - Drugs In Development, 2021

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H1N1 Subtype Infections - Drugs In Development, 2021, provides an overview of the Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline landscape.

H1N1 Infection also called as swine flu is a new kind of flu in humans. It's caused by a contagious virus. H1N1 flu infects the breathing tubes in nose, throat, and lungs. The disease is contagious. When people who have it cough or sneeze, they spray tiny drops of the virus into the air. Signs and symptoms include cough, fever, sore throat, stuffy or runny nose, body aches, headache and fatigue. Treatment includes medication (antiviral drugs).

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H1N1 Subtype Infections - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H1N1 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 7, 11, 7, 2, 43, 8 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 3, 2, 12 and 2 molecules, respectively.

Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H1N1 Subtype Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Influenza A Virus, H1N1 Subtype Infections - Overview

Influenza A Virus, H1N1 Subtype Infections - Therapeutics Development

Influenza A Virus, H1N1 Subtype Infections - Therapeutics Assessment

Influenza A Virus, H1N1 Subtype Infections - Companies Involved in Therapeutics  
Development

Influenza A Virus, H1N1 Subtype Infections - Drug Profiles

Influenza A Virus, H1N1 Subtype Infections - Dormant Projects

Influenza A Virus, H1N1 Subtype Infections - Discontinued Products

Influenza A Virus, H1N1 Subtype Infections - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Companies, 2021 (Contd..1)

Number of Products under Development by Companies, 2021 (Contd..2)

Number of Products under Development by Companies, 2021 (Contd..3)

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021 (Contd..2)

Products under Development by Companies, 2021 (Contd..3)

Products under Development by Companies, 2021 (Contd..4)

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by AbbVie Inc, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Abzyme Therapeutics LLC, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Adimmune Corp, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Akshaya Bio Inc, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Alla Chem LLC, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Allergy Therapeutics Plc, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by AlphaVax Inc, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Altimune Inc, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Ansun Biopharma Inc, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by AstraZeneca Plc, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by AVM Biotechnology LLC, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by BioTherapeutics Inc, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Blue Water Vaccines Inc, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by BlueWillow Biologics Inc, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Brandenburg Antiinfektiva GmbH, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by BunyaVax BV, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by CEL-SCI Corp, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Celestial Therapeutics Inc, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Changchun Bcht Biotechnology Co Ltd, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Chicago Biosolutions Inc, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by CHO Pharma Inc, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Cidara Therapeutics Inc, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Cilian AG, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Cocystal Pharma Inc, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by CSL Ltd, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Curevac NV, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by CytoAgents Inc, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Cytocom Inc, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Dnarx LLC, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Emergent BioSolutions Inc, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Ena Respiratory Pty Ltd, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Ena Therapeutics Pty Ltd, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by EpiVax Inc, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Etubics Corp, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by ExpreS2ion Biotech Holding AB, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by FluGen Inc, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Gamma Vaccines Pty Ltd, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Genentech USA Inc, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by GlaxoSmithKline Plc, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Greffex Inc, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by ILiAD Biotechnologies LLC, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Imutex Ltd, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Inovio Pharmaceuticals Inc, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Institute of Virology Vaccines and Sera Torlak, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by InvVax Inc, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Jiangsu Ab&b Biotechnology



Co Ltd, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Jiangsu Kanion

Pharmaceutical Co Ltd, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Johnson & Johnson, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Liaoning Cheng Da

Biotechnology Co Ltd, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Medicago Inc, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Microbiotix Inc, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by NanoViricides Inc, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by New Amsterdam Sciences Inc, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Novavax Inc, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by NuGenerex Immuno-Oncology Inc, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by PeptiDream Inc, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Pneumagen Ltd, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Recce Pharmaceuticals Ltd, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Replikins Ltd, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Revelation Biosciences Inc, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by SAB Biotherapeutics Inc, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Sanofi, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Sciogen Inc, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Seqirus Ltd, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Serum Institute of India Pvt Ltd, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Shanghai Institute of Biological Products Co Ltd, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Sonnet BioTherapeutics Holdings Inc, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by TechnoVax Inc, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Tiba Biotech LLC, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Trellis Bioscience Inc, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by UMN Pharma Inc, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Vaccibody AS, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Vacthera BioTech GmbH, 2021

Influenza A Virus, H1N1 Subtype Infections - Pipeline by Vaxart Inc, 2021



Influenza A Virus, H1N1 Subtype Infections - Pipeline by Vaxxas Inc, 2021  
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Viramatix Sdn Bhd, 2021  
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Virion Biotherapeutics, 2021  
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Vironova Medical AB, 2021  
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Vivaldi Biosciences Inc, 2021  
Influenza A Virus, H1N1 Subtype Infections - Dormant Projects, 2021  
Influenza A Virus, H1N1 Subtype Infections - Dormant Projects, 2021 (Contd..1)  
Influenza A Virus, H1N1 Subtype Infections - Dormant Projects, 2021 (Contd..2)  
Influenza A Virus, H1N1 Subtype Infections - Dormant Projects, 2021 (Contd..3)  
Influenza A Virus, H1N1 Subtype Infections - Dormant Projects, 2021 (Contd..4)  
Influenza A Virus, H1N1 Subtype Infections - Discontinued Products, 2021

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

## I would like to order

Product name: Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) - Drugs In Development, 2021

Product link: <https://marketpublishers.com/r/I69C0ED446F9EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I69C0ED446F9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

